Bombardier Inc.
17.2.2021 13:08:50 CET | Globenewswire | Press release
MONTRÉAL, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Bombardier (TSX: BBD.B) today announced that it has initiated the repayment of the total outstanding balance of $750 million drawn on its $1 billion senior secured term loan facility (the "Facility") established on August 19, 2020. Payout of the Facility, including all accrued interest and associated fees, will be completed on February 19, 2021.
About Bombardier
Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.
Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of approximately 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.
News and information is available at bombardier.com or follow us on Twitter @Bombardier.
Bombardier is a trademark of Bombardier Inc. and its subsidiaries.
All amounts in this press release are in U.S. dollars unless otherwise indicated.
For Information
Mark Masluch
Director, Communications and Public Affairs
Bombardier
Mark.Masluch@aero.bombardier.com
+1-514-855-7167
Patrick Ghoche
Vice President, Corporate Strategy and Investor Relations
Bombardier Inc.
+1-514 861 5727
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
